WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer Completes Sale of Consumer Healthcare Business 21 December 2007
Pfizer to Acquire CovX to Extend Biotherapeutics Investment 19 December 2007
Pfizer and Adolor Enter into Exclusive Worldwide Collaboration 06 December 2007
Pfizer to Acquire Coley Pharmaceutical Group 16 November 2007
Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function 06 November 2007
Taisho and Pfizer Sign a Letter of Intent for Taisho’s Schizophrenia Drug Candidate 03 November 2007
Pfizer to Appeal German Court Decision in Lipitor Patent Case 30 October 2007
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent 23 October 2007
Pfizer Reports Third-Quarter 2007 Results 19 October 2007
Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care 15 October 2007
Pfizer Launches Independent Biotherapeutics and Bioinnovation Center 05 October 2007
Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer 28 September 2007
First in a New Oral Class of HIV Medicines in 10 Years 24 September 2007
Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug 19 September 2007
Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib 12 September 2007
Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education 06 September 2007
Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death 05 September 2007
Pfizer Names Frank A. D'Amelio Chief Financial Officer 22 August 2007
UK Body Recommends Pfizer's Champix (varenicline) for Smokers 30 May 2007
  • Start
  • Prev
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.